Back

Perspectives on results from recent CVOTs in type 2 diabetes.

26 August 2017 (16:10 - 16:20)
Organised by:
Congress Presentation Part of: Improving cardiovascular outcomes in type 2 diabetes: a novel role for GLP-1 receptor agonists? Diabetes, dysglycaemia and metabolic syndrome Open Access ESC Congress 2017

About the speaker

Photo
Professor Lars Ryden

Karolinska Institute, Stockholm (Sweden)

4 More presentations in this session

Presentation thumbnail
Introduction: cardiovascular disease in type 2 diabetes – Where do we come from.
Professor L. Ryden (Stockholm, SE)
Slides Video
Presentation thumbnail
Cardiovascular effects of GLP-1 receptor agonists.
Doctor J. Plutzky (Boston, US)
Slides Video
Presentation thumbnail
Results from the LEADER cardiovascular outcomes trial.
Professor N. Poulter (London, GB)
Slides Video
Presentation thumbnail
Panel discussion - Improving CV outcomes in type 2 diabetes: A novel role for GLP-1 receptor agonists?
Professor L. Ryden (Stockholm, SE) Professor N. Poulter (London, GB) Doctor J. Plutzky (Boston, US)
Slides Video

Access the full session

Session thumbnail
Improving cardiovascular outcomes in type 2 diabetes: a novel role for GLP-1 receptor agonists?

The Event

Event poster

ESC Congress 2017

26 August 2017 16:10 CET
You may be interested in
thumbnail
Congress Session
Guidelines in Practice: 2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes
27 August 2023
thumbnail
Congress Presentation
Absolute treatment effects of novel oral antidiabetic drugs on cardiovascular mortality and hospitalization for heart failure: a meta-analysis of digitalized individual patient outcomes
27 August 2022
thumbnail
Congress Presentation
Qualifying event proximity, cardiovascular risk, and benefit of empagliflozin in patients with type 2 diabetes and stable atherosclerosis in the EMPA-REG OUTCOME trial
31 August 2019
thumbnail
Congress Presentation
Effect of oral semaglutide on CV outcomes across the vascular disease spectrum, from no vascular disease to polyvascular disease, in high-risk type 2 diabetes
1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources